Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Tumor|Breast Cancer|Cancer of the Breast|Estrogen Receptor- Negative Breast Cancer|HER2- Negative Breast Cancer|Progesterone Receptor- Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer|Triple-negative Metastatic Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: nab-Paclitaxel|DRUG: Carboplatin|DRUG: Gemcitabine
Sponsor: Celgene